Poxel Initiates Reorganization Amid Financial Struggles

Poxel SA has announced significant corporate changes due to financial challenges following a failed shareholder meeting in February 2025 that led to default conditions. The firm, unable to finalize a financial partnership or product sale, is set to restructure its operations.

The company has filed for insolvency and seeks reorganization under Lyon's Court for Economic Activities. All current Board of Directors members will resign, with a new executive team expected soon. These steps are part of a transition plan agreed with their senior creditor, IPF Partners.

Poxel's shares are suspended as of July 30, 2025, pending court decisions expected in early August. Despite setbacks, Poxel continues its mission to innovate in chronic disease treatments, though future financial timelines remain uncertain.